327 related articles for article (PubMed ID: 36115523)
21. Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Strober B; Blauvelt A; Warren RB; Papp KA; Armstrong AW; Gordon KB; Morita A; Alexis AF; Lebwohl M; Foley P; Kisa RM; Colston E; Wang T; Banerjee S; Thaçi D
J Eur Acad Dermatol Venereol; 2024 Mar; ():. PubMed ID: 38451052
[TBL] [Abstract][Full Text] [Related]
22. Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.
Papp KA; Gordon K; Strober B; Zhuo J; Becker B; Zhong Y; Beaumont JL; Pham TP; Kisa R; Napoli AA; Banerjee S; Armstrong AW
JAMA Dermatol; 2024 Feb; 160(2):204-209. PubMed ID: 38117487
[TBL] [Abstract][Full Text] [Related]
23. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
Strober B; Thaçi D; Sofen H; Kircik L; Gordon KB; Foley P; Rich P; Paul C; Bagel J; Colston E; Throup J; Kundu S; Sekaran C; Linaberry M; Banerjee S; Papp KA
Immunotherapy; 2023 Aug; 15(11):787-797. PubMed ID: 37150956
[TBL] [Abstract][Full Text] [Related]
24. Deucravacitinib for the Treatment of Psoriatic Disease.
Lé AM; Puig L; Torres T
Am J Clin Dermatol; 2022 Nov; 23(6):813-822. PubMed ID: 35960487
[TBL] [Abstract][Full Text] [Related]
25. Deucravacitinib in moderate-to-severe psoriasis.
Vu A; Maloney V; Gordon KB
Immunotherapy; 2022 Nov; 14(16):1279-1290. PubMed ID: 36373503
[TBL] [Abstract][Full Text] [Related]
26. Deucravacitinib in the treatment of psoriasis.
Estevinho T; Lé AM; Torres T
J Dermatolog Treat; 2023 Dec; 34(1):2154122. PubMed ID: 36453809
[TBL] [Abstract][Full Text] [Related]
27. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
[TBL] [Abstract][Full Text] [Related]
28. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF; Bagel J; Tyring SK; Hong HC; Pavlovsky L; Vender R; Pinter A; Reich A; Drogaris L; Wu T; Patel M; Soliman AM; Photowala H; Stakias V; Richter S; Papp KA
Br J Dermatol; 2023 Oct; 189(5):540-552. PubMed ID: 37488811
[TBL] [Abstract][Full Text] [Related]
29. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K; Reich K; Leonardi CL; Kircik L; Chimenti S; Langley RG; Hu C; Stevens RM; Day RM; Gordon KB; Korman NJ; Griffiths CE
J Am Acad Dermatol; 2015 Jul; 73(1):37-49. PubMed ID: 26089047
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.
Fiorillo L; Becker E; de Lucas R; Belloni-Fortina A; Armesto S; Elewski B; Maes P; Oberoi RK; Paris M; Zhang W; Zhang Z; Arkin L
J Am Acad Dermatol; 2024 Jun; 90(6):1232-1239. PubMed ID: 38266683
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
Papp KA; Kaufmann R; Thaçi D; Hu C; Sutherland D; Rohane P
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Mease PJ; Deodhar AA; van der Heijde D; Behrens F; Kivitz AJ; Neal J; Kim J; Singhal S; Nowak M; Banerjee S
Ann Rheum Dis; 2022 Jun; 81(6):815-822. PubMed ID: 35241426
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y
J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
[TBL] [Abstract][Full Text] [Related]
35. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary.
Armstrong AW; Gooderham M; Warren RB; Papp KA; Strober B; Thaçi D; Morita A; Szepietowski JC; Imafuku S; Colston E; Throup J; Kundu S; Schoenfeld S; Linaberry M; Banerjee S; Blauvelt A
Immunotherapy; 2023 Aug; 15(12):963-973. PubMed ID: 37150952
[TBL] [Abstract][Full Text] [Related]
36. Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.
Tehlirian C; Singh RSP; Pradhan V; Roberts ES; Tarabar S; Peeva E; Vincent MS; Gale JD
J Am Acad Dermatol; 2022 Aug; 87(2):333-342. PubMed ID: 35398218
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
Mrowietz U; Barker J; Conrad C; Jullien D; Gisondi P; Flower A; Reddy J; Paris M; Picard H; Jardon S; Augustin M
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):348-355. PubMed ID: 36300769
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
39. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Morand E; Pike M; Merrill JT; van Vollenhoven R; Werth VP; Hobar C; Delev N; Shah V; Sharkey B; Wegman T; Catlett I; Banerjee S; Singhal S
Arthritis Rheumatol; 2023 Feb; 75(2):242-252. PubMed ID: 36369798
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]